DeCure for Rosette-forming glioneuronal tumor of fourth ventricule
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for rosette-forming glioneuronal tumor of fourth ventricule — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRosette-forming glioneuronal tumor of fourth ventricule maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rosette-forming glioneuronal tumor of fourth ventricule is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) — PIK3CA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4JPS · 2.2 Å · ligand (2S)-N~1~-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide (1LT). Experimental structure, not a prediction.
What the evidence adds up to
Rosette-forming glioneuronal tumor of the fourth ventricle is an extremely rare, newly described WHO grade I brain tumour, included in the WHO classification only in 2007. The three abstracts report single cases or cytology smears, not clinical trials. One case was a teenager; another was a 19-year-old male. In one report the tumour was misdiagnosed as ependymoma on squash cytology. The authors stress that cytopathologists must be aware of this entity to avoid confusion with more common neoplasms at that site.
Complete surgical excision is stated to be the treatment of choice, based on the tumour’s WHO grade I designation. In the 2009 case, the tumour was identified by MR imaging, surgically removed, and the diagnosis confirmed morphologically and immunohistochemically. No data on long-term outcomes, recurrence rates, or survival are given in any of these abstracts.
No drug treatment is mentioned in any of the three abstracts. There is no evidence for any pharmacological intervention, repurposed or otherwise, for this tumour. What is missing is any prospective series, any trial of adjuvant therapy, any data on progression-free or overall survival, and any systematic collection of outcomes beyond single case reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Advances in Anatomic Pathology · 2008 · 47 citations
The Expanding Family of Glioneuronal Tumors
AbstractThree new entities have been recently added to the group of glioneuronal tumors in the most recent update of the World Health Organization classification of tumors of the central nervous system: papillary glioneuronal tumor, rosetted glioneuronal tumor with neuropil-like islands, and rosette-forming glioneuronal tumor of the fourth ventricle. These tumors are relatively infrequent lesions, and because of that, they can be challenging to diagnose for the practicing pathologist. In this article, we summarize the clinical and pathologic findings of these new lesions.
Journal of Cytology · 2014 · 11 citations · open access
Rosette forming glioneuronal tumor of the fourth ventricle in squash cytology smear
AbstractRosette forming glioneuronal tumor (RGNT) is a recently recognized and extremely rare glioneuronal tumor occurring in the fourth ventricle. It is crucial for the cytopathologist to be aware of this entity as it can be easily mistaken for more common neoplasms occurring at this site. We present here the cytology of such a rare case of RGNT that was misdiagnosed as ependymoma. The varying cytological features of this entity, as well as the common diagnostic difficulties encountered in cytology, are highlighted in this report.
Central European Neurosurgery · 2010 · 9 citations
Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle
AbstractKomori et al. (2002) were the first authors to recognize the existence of a new brain tumor entity, rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle. The authors described 11 cases of this distinctive tumor of the posterior fossa [6]. A few further RGNT cases were published in the following 5 years [1] [2] [4] [5] [8] [10], eventually leading to the inclusion of RGNT in the 4th edition of the WHO brain tumor classification as a benign primary brain tumor classified as WHO grade 1 [7] [9].
Teenager with Rosette-Forming Glioneural Tumour of the Fourth Ventricle: Case Study of a Rare Tumour
AbstractTeenager with Rosette-Forming Glioneural Tumour of the Fourth Ventricle: Case Study of a Rare Tumour We report the case of uncommon rare tumour of the fourth ventricle in young person. This diagnosis is included to WHO classification only in 2007. Tumour was identified by the MR imaging, later on surgically removed with post-operative MRI control scan. Diagnosis-rosette-forming tumour of the fourth ventricle- was confirmed both morphologically and immunohistochemically.
International Journal of Neuroscience · 2021 · 0 citations
Role of intra-operative squash cytology in rosette-forming glioneuronal tumor of the fourth ventricle: a case report
AbstractRosette-forming glioneuronal tumor (RGNT) of the 4th ventricle is a newly described WHO grade I brain tumor included in recent WHO classification of CNS tumors. It is a biphasic tumor thought to originate from pluripotent progenitor cells of subependymal plate. Intra-operative diagnosis plays an important role, as complete surgical excision is the treatment of choice. We are reporting a case of RGNT in a 19 years-old young male emphasizing the intra-operative pathological pointers and their role in accurate diagnosis for the suitable surgical intervention.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
